Common Drugs of Abuse - Drug Detection and Monitoring Chart - Opioids Detection Guide

Aug 23, 2026

Upload by Mali

Drug Detection and Monitoring Chart provides a structured overview of commonly abused substances used in screening and ongoing monitoring. It organizes drug class and drug analytes, including common and street names, DEA schedule, routes of use, and the drug or metabolite monitored. For each opioid, it summarizes addiction and withdrawal characteristics and gives average detection windows in urine and oral fluid to support informed, compliant selection and tracking of test results.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Drug Detection and Monitoring Chart

Drug class and drug analytes

Opioids: drug/metabolite monitored and detection times

Synthetic opioids and withdrawal considerations

Stimulants and benzodiazepines

Common drugs of abuse. Drug Detection and Monitoring Chart Alere Toxicology helps you make informed decisions. The use of this chart will help you identify, understand, and monitor commonly abused substances. Turn to Alere to perform compliant, accurate, and reliable drug screens customized for your detection and monitoring needs. E-mail us: [toxicology@alere.com | Visit](toxicology@alere.com | Visit) us: [aleretoxicology.com](aleretoxicology.com) DRUG CLASS AND DRUG ANALYTES COMMON DRUG NAMES STREET NAMES DEA SCHEDULE1 WAYS USED ADDICTION AND WITHDRAWAL DRUG/METABOLITE MONITORED AVERAGE DETECTION TIME URINE AVERAGE DETECTION TIME ORAL FLUID OPIATES / OPIOIDS | Codeine | Tylenol® \#3 | Schoolboy | Schedule II | Oral; intrarectal; intramuscular; subcutaneous | Moderate-to-low risk of physical or psychological dependence. Withdrawal symptoms may include drug craving, runny nose, yawning, sweating, insomnia, weakness, stomach cramps, etc. | Codeine, morphine | 1-3 days | 1-2 days | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Hydrocodone | Lorcet® , Lortab® , Hycodan® , Norco® , Vicodin® , Vicoprofen® | Hydros, dones, vics, itchies | Schedule II | Oral | Moderate potential of physical or psychological dependence. Withdrawal symptoms may include severe pain, pins and needles, sweating, extreme anxiety, restlessness, sneezing, etc. | Hydrocodone, hydromorphone, norhydrocodone | 1-3 days | 1-2 days | | Hydromorphone | Dilaudid® , Hymorphan® | Juice, dillies, M2s, hospital heroin | Schedule II | Oral; intramuscular; intravenous; subcutaneous; intranasal; rectal; sublingual; transmucosal; buccal; transdermal | Moderate-to-high risk of physical or psychological dependence. Withdrawal symptoms may include shaking, cold sweats, diarrhea, vomiting, self-doubt, emptiness, etc. | Hydromorphone | 1-3 days | 1-2 days | | Morphine | Avinza® , Kadian® , MS Contin® , MSIR® , Roxanol® , Embeda® | M, morph | Schedule II | Smoking; snorting; oral; rectal; subcutaneous; intramuscular; intravenous; intrathecal | High potential for physical or psychological dependence. Withdrawal symptoms may include several stages ranging from drug craving and anxiety to vomiting or loss of appetite. | Morphine | 1-3 days | 1-2 days | | Oxycodone | Tylox® , Percocet® , Percodan® , OxyContin® , OxyIR® , Roxicodone® | Oxy-cofins, killers, percs | Schedule II | Oral; intramuscular; intravenous;
intranasal; subcutaneous; transdermal; rectal; epidural | Moderate-to-high risk of physical or psychological dependence. Withdrawal symptoms may include anxiety, panic attacks, nausea, muscle pain, fevers, etc. | Oxycodone, oxymorphone, noroxycodone | 1-3 days | 1-2 days | | Oxymorphone | Opana ER® , Opana IR® , Numorphan® | Blues, nu-blues, biscuits, blue heaven | Schedule II | Intravenous; intramuscular; subcutaneous; oral; rectal; intranasal | High risk of physical or psychological dependence. Withdrawal symptoms may include anxiety, panic attacks, nausea, muscle pain, fevers, etc. | Oxymorphone | 1-3 days | 1-2 days | SYNTHETIC OPIOIDS Buprenorphine Fentanyl Meperidine Methadone Pentazocine Propoxyphene Tapentadol Tramadol Suboxone® , Subutex® , Buprenex® , Butrans® Actiq® , Fentora® , Onsolis® , Duragesic® , Sublimaze® Demerol® Methodose® , Dolophine® Talwin® Darvocet® , Darvon® Nucynta® Ryzolt® , Ultracet® , Ultram® N/A N/A Demmies, pain killer Dollies, meth T’s Pain killer N/A N/A Schedule III Schedule II Schedule II Schedule II Schedule IV Nonscheduled by itself, Schedule IV in combination. Schedule II Schedule IV Sublingual; intramuscular; intravenous; transdermal; intranasal; rectal Transdermal; intramuscular; intravenous; oral; sublingual; buccal Oral; intranasal; rectal; intravenous Oral; intravenous; insuflation; sublingual; rectal Oral; intravenous; intramuscular Oral; intravenous; rectal Oral Oral; intravenous; intramuscular; rectal; subli

FAQs

What information does the drug detection and monitoring chart include for each substance?

It includes drug class/analytes, common and street names, DEA schedule, routes of use, addiction and withdrawal notes, the drug/metabolite monitored, and average detection time in urine and oral fluid.

What are the average detection times for common opioids in urine and oral fluid?

The chart lists opioid-specific average detection windows, with urine typically around 1–3 days for several opioids shown and oral fluid around 1–2 days. Values vary by substance and route.

How does the chart support compliant drug screening and ongoing monitoring needs?

It helps users identify, understand, and monitor commonly abused substances by pairing analyte targets with typical detection windows and dependence/withdrawal considerations for more reliable interpretation of screening results.

Aug 23, 2026

Upload by Mali